Anaplastic Malignant Neoplasm

In a clinical study of 63 recurrent glioma patients, de novo glioblastoma patients treated with cetuximab monotherapy (n=27) and harboring IDH1 codon 132 mutation were associated with improved overal… (full text at CIViC)

PMID 22199315 · Lv et al., 2011 · Open in CIViC

In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients.

PMID 19228619 · Yan et al., 2009 · Open in CIViC

In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients.

PMID 19228619 · Yan et al., 2009 · Open in CIViC

From a retrospective review of 38,095 tumor samples from 33,997 patients that underwent fusion screening at Memorial Sloan Kettering Cancer Center, 87 tumors were found to be positive for an NTRK1, NT… (full text at CIViC)

PMID 31375766 · Solomon et al., 2020 · Open in CIViC

An MRI in a previously healthy 6-year-old boy now presenting with neurologic abnormalities and seizures revealed a mass obstructing the foramen of Monro and diffuse leptomeningeal dissemination. The p… (full text at CIViC)

PMID 34651095 · Mangum et al., 2021 · Open in CIViC

Phase II trial of sunitinib in 40 patients with first recurrence of primary glioblastoma. Median PFS 2.2 mo, median OS 9.2 mo, 5 stable disease >=6 months, no objective responses, so primary study end… (full text at CIViC)

PMID 24311637 · Hutterer et al., 2014 · Open in CIViC

A retrospective study of 178 glioblastoma patients found that LRP1B deletion (complete transcript, N=4 or focal transcript deletion of >150kb, N=13) was associated with a lower progress free survival … (full text at CIViC)

PMID 26428308 · Tabouret et al., 2015 · Open in CIViC

Through the analysis of 10 patient-derived glioblastoma cells, AMG232 was found to have increased sensitivity in comparison to RG7112 with the average IC50 of 76nM vs. 720nM; thus indicating a 9.5 fol… (full text at CIViC)

PMID 30022047 · Her et al., 2018 · Open in CIViC

A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizoti… (full text at CIViC)

PMID 22162573 · Chi et al., 2012 · Open in CIViC

A 74-year-old woman with stage II Pulmonary Sarcomatoid Carcinoma (PSC) was treated with neoadjuvant platinum/taxane chemotherapy with no improvement. Chemotherapy was stopped due to resistance and po… (full text at CIViC)

PMID 26215952 · Liu et al., 2016 · Open in CIViC

A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation. In 18 cases with MET exon 14 skipping mutations, 2.6% had adenocarcinoma, 4.8% had adenosquamous cel… (full text at CIViC)

PMID 26847053 · Tong et al., 2016 · Open in CIViC

A 65-year old male (non-smoker) presented with advanced sarcomatoid non-small-cell lung cancer harboring a MET exon 14 skipping mutation with elevated PDL1 levels (tumor proportion score of 80%). Afte… (full text at CIViC)

PMID 35871685 · Gonugunta et al., 2022 · Open in CIViC

A 58-year old male (non-smoker/non-drinker) was diagnosed with metastatic adenocarcinoma with sarcomatoid components. A tissue sample revealed a MET exon 14 skipping mutation and the patient was treat… (full text at CIViC)

PMID 35110965 · Gu et al., 2022 · Open in CIViC

A 61-year old male (non-smoker) was diagnosed with sarcomatoid non-small-cell lung cancer (CK+, TTF1+, and vimentin+). Genomic profiling showed two MET alterations that showed exon 14 skipping mutatio… (full text at CIViC)

PMID 26709483 · Lee et al., 2015 · Open in CIViC

A 83-year old woman presented with sarcomatoid squamous cell carcinoma. Next-generation sequencing revealed a MET exon 14 skipping mutation (c.3028+3A>G) and the patient was treated with crizotinib (2… (full text at CIViC)

PMID 36147925 · Sun et al., 2022 · Open in CIViC

In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, MGMT expression was found to be inversely correlated with survival. Patients in the MGMT high expression group (n=… (full text at CIViC)

PMID 24248532 · Wang et al., 2014 · Open in CIViC

In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters.

PMID 15758010 · Hegi et al., 2005 · Open in CIViC

MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.

PMID 11070098 · Esteller et al., 2000 · Open in CIViC

The T allele of the rs16906252 SNP was associated with MGMT methylation and low protein expression. Germline presence of the T allele increased the risk of glioblastoma development (adjusted odds rati… (full text at CIViC)

PMID 25910840 · Rapkins et al., 2015 · Open in CIViC

In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median… (full text at CIViC)

PMID 17442989 · Chinot et al., 2007 · Open in CIViC

In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immun… (full text at CIViC)

PMID 21331613 · Watanabe et al., 2011 · Open in CIViC

The expression of a set of miRNAs was evaluated by qRT-PCR in 124 astrocytoma (grade I-IV) samples and 60 adjacent normal tissue samples in order to determine miRNAs with altered expression in astrocy… (full text at CIViC)

PMID 20219352 · Zhi et al., 2010 · Open in CIViC

This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC)

PMID 35945463 · Lucas et al., 2022 · Open in CIViC

This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC)

PMID 35945463 · Lucas et al., 2022 · Open in CIViC

RNAseq data of 162 glioblastoma patients identified NTRK1 fusions with both NFASC and BCABN. By analyzing exome and RNA data, the NFASC-NTRK1 fusion was found to retain NTRK1's kinase and transmembran… (full text at CIViC)

PMID 24647444 · Kim et al., 2014 · Open in CIViC

In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom… (full text at CIViC)

PMID 23598171 · Mossé et al., 2013 · Open in CIViC

NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized. In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib … (full text at CIViC)

PMID 18089725 · Christensen et al., 2007 · Open in CIViC

In an in vitro study, cell lines expressing NPM-ALK I1171N, SUPM2CR03 (endogenous expression) and Ba/F3 (overexpression), demonstrated resistance to crizotinib treatment (IC50: 338 nmol/L and IC50: 21… (full text at CIViC)

PMID 23239810 · Ceccon et al., 2013 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated resistance to crizotinib treatment (IC50: 345.03… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK T1151M co-mutation, demonstrated resistance to ceritinib treatment (IC50: 95.78 n… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC)

PMID 30715997 · Wen et al., 2019 · Open in CIViC

In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC)

PMID 30715997 · Wen et al., 2019 · Open in CIViC

Kaplan-Meier analysis of PLK1 gene expression showed that elevated expression is significantly associated with shorter disease-free survival in GBM (p=9.1e-11).

PMID 32180229 · Li et al., 2020 · Open in CIViC

Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor progno… (full text at CIViC)

PMID 27001570 · Bouffet et al., 2016 · Open in CIViC

Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasi… (full text at CIViC)

PMID 27683556 · Johanns et al., 2016 · Open in CIViC

In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII… (full text at CIViC)

PMID 25939761 · Zahonero et al., 2015 · Open in CIViC

49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort o… (full text at CIViC)

PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC

Rasheed et al. identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compar… (full text at CIViC)

PMID 9331072 · Rasheed et al., 1997 · Open in CIViC

In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC)

PMID 30715997 · Wen et al., 2019 · Open in CIViC

Bostrom et al identified R173C in the tumor sample of 1 subject (out of 36 glioblastomas tested). By PCR mRNA expression of PTEN was assayed for tumor samples harboring PTEN variants. PTEN expression… (full text at CIViC)

PMID 9426052 · Boström et al., 1998 · Open in CIViC

Fults et al identified 1 R173C mutation in a glioblastoma (of 45 tested). The tumor also displayed either all or partial LOH of 10q, there was no further resolution of the LOH size or mutational testi… (full text at CIViC)

PMID 9499454 · Fults et al., 1998 · Open in CIViC

PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients.

PMID 22479427 · Carico et al., 2012 · Open in CIViC

Authors demonstrated that a flag-tagged QKI::NTRK2 (e6::e16) fusion was able to transform Ink4a−/−/Arf−/− astrocytes, and these cells induced astrocytomas when injected intracranially into mice. QKI… (full text at CIViC)

PMID 27402815 · Ni et al., 2017 · Open in CIViC